Sonoma Pharmaceuticals, Inc (SNOA) Fair Value & Analysis
Healthcare · US · Market cap $5.6M
Sonoma Pharmaceuticals, Inc
SNOA · US
Fair value as of: Jul 19, 2026
From 1 valuation models · updated today
Share price +5.2% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.01 – $5.35 · fair‑value band $0.3910 – $0.7480 · the $1.21 price screens above the $0.5950 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sonoma Pharmaceuticals, Inc (SNOA) currently trades at $1.21, while our model-based Fair Value estimate is $0.5950, implying the stock looks roughly 50.8% overvalued today. We read business quality at 28/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Sonoma Pharmaceuticals, Inc generated revenue of $19.5M at a net margin of -16.3%. Revenue grew 48.1% year over year. It earns a return on equity of -84.6%. The balance sheet holds a net cash position of $5.1M. Fundamentals as of Jul 19, 2026
Our scenario range runs from $0.3910 (bear case) to $0.7480 (bull case); at $1.21, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside, at -51%, SNOA screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sonoma Pharmaceuticals, Inc reported revenue of $14.3M in FY2025 versus $18.6M in FY2021, a compound −6.4%/yr. Reported net income was −$3.5M in FY2025.
Is SNOA fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,538 | ₹1,161 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sonoma Pharmaceuticals, Inc (SNOA) undervalued?
What is the fair value of SNOA?
What is the quality score of SNOA?
What is the revenue of Sonoma Pharmaceuticals, Inc (SNOA)?
What is the net profit margin of SNOA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Sonoma Pharmaceuticals, Inc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.